GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Net Issuance of Debt

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Net Issuance of Debt : ¥5.9 Mil (TTM As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Staidson (Beijing) Biopharmaceuticals Co's net issuance of debt for the three months ended in Mar. 2025 was ¥-10.0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2025 was ¥5.9 Mil.


Staidson (Beijing) Biopharmaceuticals Co Net Issuance of Debt Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Net Issuance of Debt Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.00 -48.00 - 28.80 1.20

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -14.13 30.00 -10.00

Staidson (Beijing) Biopharmaceuticals Co Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staidson (Beijing) Biopharmaceuticals Co Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Staidson (Beijing) Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Executives
Zhang Hong Shan Supervisors
Zheng Hong Supervisors
Cheng Jiang Hong Executives
Feng Yu Jing Executives
Ma Li Na Secretary, Director
Zhou Zhi Wen Director
Wang Huan Securities Affairs Representative
Zhang Rong Qin Executives
Xu Jiang Ping Executives
Cao Hai Yan Supervisors
Sun Yan Fang Executives
Jiang Li Xin Director
Gu Jian Ping Director
Xu Xiang Qing Supervisors
Gu Zhen Qi Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines